Evidence map›Paper›PMID 30154665›Full record

ArticleOncoTargets and therapy2018

Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-β A.

Yuxiao Zheng, Yiren Gao, Xiao Li, Shuhui Si, Haoxiang Xu, Feng Qi, Jun Wang, Gong Cheng, Lixin Hua, Haiwei Yang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
  9. Meta-analysis of the prognostic value ofCancer management and research · 2019
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yuxiao ZhengDepartment of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.
Yiren GaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Xiao LiDepartment of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.
Shuhui SiResearch Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Haoxiang XuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Feng QiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Jun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Gong ChengDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Lixin HuaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Haiwei YangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China, lixinhua@njmu.edu.cn, haiweiyang@njmu.edu.cn.
Nanjing Medical University · CNJiangsu Cancer Hospital · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/purposeLong non-coding RNAs (lncRNAs) have emerged as key molecules in initiation and progression of prostate cancer (PCa). In this study, we aimed to explore the role of lncRNA NAP1L6 in the development and progression of PCa. MATERIALS AND

methodsWe identified that lncRNA NAP1L6 was over-expressed both in PCa tissues and cell lines by gene expression array profiling. The expression level of NAP1L6 in 75 PCa tissues and adjacent tissues was detected by RT-PCR. Next, the correlations between NAP1L6 expression and clinical features of patients with PCa were analyzed by paired

resultsUsing microarray analysis, we identified 412 lncRNAs and 1245 mRNAs to be significantly differentially expressed in three PCa samples when compared with adjacent non-tumor tissues (ANTT) (fold-change ≥2.0 or ≤0.5,

conclusionlncRNA NR6A1 might play an oncogenic role in PCa initiation and progression by regulating the expression of INHBA, and might act as a novel prognostic biomarker for PCa treatment.

Indexed as

INHBAlong non-coding RNANR6A1prognosisprostate cancer

Identifiers

PMID30154665
PMCPMC6103656
OpenAlexW2885204469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.